The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Abstract
Rationale Transforming growth factor (TGF)-beta has a central role in driving many of the pathological processes that characterize pulmonary fibrosis. Inhibition of the integrin alpha(v)beta6, a key activator of TGF-beta in lung, is an attractive therapeutic strategy, as it may be possible to inhibit TGF-beta at sites of alpha(v)beta6 up-regulation without affecting other homeostatic roles of TGF-beta. Objectives To analyze the expression of alpha(v)beta6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of alpha(v)beta6-mediated TGF-beta activation in murine bleomycin-induced pulmonary fibrosis. Methods Lung biopsies from patients with a diagnosis of systemic sclerosis or idiopathic pulmonary fibrosis were stained for alpha(v)beta6 expression. A range of concentrations of a monoclonal antibody that blocks alpha(v)beta6-mediated TGF-beta activation was evaluated in murine bleomycin-induced lung fibrosis. Measurements and main results Alpha(v)beta6 is overexpressed in human lung fibrosis within pneumocytes lining the alveolar ducts and alveoli. In the bleomycin model, alpha(v)beta6 antibody was effective in blocking pulmonary fibrosis. At high doses, there was increased expression of markers of inflammation and macrophage activation, consistent with the effects of TGF-beta inhibition in the lung. Low doses of antibody attenuated collagen expression without increasing alveolar inflammatory cell populations or macrophage activation mark…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its mechanism involves specifically interrupting epithelial cell-derived TGF-b activation by the avb6 integrin, thereby disrupting the avb6/TGF-b positive feedback loop driving fibrosis progression (132).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [132]
In the citing paper
“The pro-inflammatory cytokine IL-17A was identified as a key inducer of fibrosis in several different organ systems, including the lung, liver, kidney, heart, and skin109–114”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [112]
In the citing paper
“Experiments with IL-17A- and IL-17RA-deficient mice, as well as therapeutic studies with IL-17A neutralizing monoclonal antibodies confirmed a role for IL-17A signaling in the development of fibrosis in multiple tissues110–112,116–118”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [112]
Citations
Cites
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206 · cited 1×
“In addition to its profibrotic activities, TGF-b plays a number of other homeostatic roles in inflammation, immune tolerance, and cancer biology (20).”
BackgroundMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Self-citationKim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“In addition, recent data points toward a critical role of avb6-mediated TGF-b activation in promoting epithelialto-mesenchymal cell transition, which may be an important source of fibroblasts in lung injury (51).”
BackgroundSelf-citationSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050 · cited 1×
“Adenoviral overexpression studies show that TGF-b is unusual in its ability to promote lung fibrosis in vivo in the absence of prominent inflammation (7).”
BackgroundZiyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794 · cited 10×
“Although some level of inflammation is a consistent feature of the disease, the lack of efficacy of immunesuppressive treatment and the apparent development and progression of fibrosis in the absence of significant inflammation in some patients have led some to propose that IPF is not the result of chronic inflammatio…”
BackgroundInfluentialSharma, K., Jin, Y., Guo, J., & Ziyadeh, F. N. (1996) · Diabetes · doi:10.2337/diab.45.4.522 · Cited by 662
Varga, J., Rosenbloom, J., & Jimenez, S. A. (1987) · Biochemical Journal · doi:10.1042/bj2470597 · Cited by 591
Travis, W. D., Matsui, K., Moss, J., & Ferrans, V. J. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200001000-00003 · Cited by 530 · cited 1×
“The only NSIP sample showing high-intensity staining for avb6 was an NSIP fibrosing variant, which is a pathology associated with more fibrosis than typical NSIP, and may be more closely related to UIP pathology (40).”
Background
Research works printed but not linked: 5
- 1999, Am J Physiol, 276, L814
- 2004, Am J Respir Crit Care Med, 171, 889
- 2000, Kidney Int, 58, 2310
- 2003, Nature, 422, 130
- 2005, FASEB J, 19, 1
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
Self-citationPathogenesis of Idiopathic Pulmonary Fibrosis
Wolters, P. J., Collard, H. R., & Jones, K. D. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104706 · Cited by 862
“During the development of lung fibrosis, AECs express increased levels of the integrin αvβ6 (54), which can bind to the arginine-glycine-aspartate (RGD) sequence of LAP (55).”
Metadata
- Authors
- Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., Goyal, J., Feghali-Bostwick, C. A., Matteson, E. L., O'Hara, C., Lafyatis, R., Davis, G. S., Huang, X., Sheppard, D., & Violette, S. M.
- Affiliations
- Biogen (United States) (US)
- Departments of Exploratory Biology, Fibrosis, Protein Chemistry, Gene Discovery, Molecular Profiling, and Clinical Sciences and Technology, Biogen Idec, Cambridge, Massachusetts
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
- Mayo Clinic (US)
- Section of Rheumatology, Department of Pathology, Boston University School of Medicine, Boston, Massachusetts
- Boston University (US)
- University of Vermont (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-01
- Volume
- 177
- Issue
- 1
- Pages
- 56-65
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2052917153
- Cited by
- 420
- References
- 56
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 18 · 2023: 20 · 2022: 17 · 2021: 37 · 2020: 25 · 2019: 24 · 2018: 32 · 2017: 27 · 2016: 27 · 2015: 26 · 2014: 27 · 2013: 26 · 2012: 33
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R37HL053949)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Keywords
- pulmonary fibrosis, TGF-beta activation, monoclonal antibody therapy, bleomycin-induced lung fibrosis, systemic sclerosis, idiopathic pulmonary fibrosis, lung inflammation, macrophage activation, collagen expression
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Collagen, Disease Models, Animal, Dose-Response Relationship, Drug, Mice, Inbred BALB C, Pulmonary Alveoli, Pulmonary Fibrosis, Scleroderma, Systemic, Integrins, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation. https://app.cochat.ai/papers/10.1164/rccm.200706-805oc
- The paper
- Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., Goyal, J., Feghali-Bostwick, C. A., Matteson, E. L., O'Hara, C., Lafyatis, R., Davis, G. S., Huang, X., Sheppard, D., & Violette, S. M. (2008). Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200706-805oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.